Review article: Drug-induced liver injury in clinical practice

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 1, 2010, Pages 3-13

  Bjornsson E ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANTIBIOTIC AGENT; AZATHIOPRINE; CARBAMAZEPINE; CARNITINE; CHLORPROMAZINE; DANTRON; DICLOFENAC; DISULFIRAM; ERYTHROMYCIN; ESTROGEN; FLUCLOXACILLIN; HALOTHANE; ISONIAZID; MACROLIDE; METHOTREXATE; MINOCYCLINE; NIMESULIDE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYTOIN; PLACEBO; QUINIDINE; STEROID; UNINDEXED DRUG; VALPROIC ACID;

AUTOIMMUNE HEPATITIS; CAUSAL ATTRIBUTION; CHOLESTASIS; CHOLESTATIC HEPATITIS; CHRONIC HEPATITIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DUCTOPENIA; FIBROSIS; GRANULOMATOUS HEPATITIS; HUMAN; HYPERTRANSAMINASEMIA; JAUNDICE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER INJURY; LIVER METABOLISM; LIVER NECROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; NODULAR REGENERATIVE HYPERPLASIA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 77953210655     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04320.x     Document Type: Review

References (94)

1. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009 32 : 55 68.
2. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008 47 : 2003 2009.
3. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002 22 : 145 155.
4. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002 36 : 451 455.
5. De Valle MB, Av Klinteberg V, Alem N, et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006 24 : 1187 1195.
6. de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004 58 : 71 80.
7. Bjørneboe M, Iversen O, Olsen S. Infective hepatitis and toxic jaundice in a municipal hospital during a five year period: Incidence and prognosis. Acta Med Scand 1967 182 : 491 501.
8. Malchow-Møller A, Matzen P, Bjerregaard B, et al. Causes and characteristics of 500 consecutive causes of jaundice. Scand J Gastroenterol 1981 16 : 1 6.
9. Whitehead MW, Hainsworth I, Kingham JGC. The causes of obvious jaundice in South West Wales: 2000. Gut 2001 48 : 409 413.
10. Björnsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003 38 : 86 94.
11. Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the united states. Am J Gastroenterol 2006 101 : 1 5.
12. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005 61 : 135 143.
13. Bjornsson E, Kalaitzakis E, Av Klinteberg V, et al. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 2007 26 : 79 85.
14. Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009 50 : 511 517.
15. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005 129 : 512 521.
16. Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007 25 : 1411 1421.
17. Zimmerman H. Hepatotoxicity the adverse effects of drugs and other chemicals on the liver.
18. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005 28 : 351 370.
19. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008 23 : 192 202.
20. Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in Disulfiram-induced liver injury. J Hepatology 2006 44 : 791 797.
21. Bjornsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008 118 : 281 290.
22. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001 33 : 308 310.
23. Lucena MI, Andrade RJ, Rodrigo L, et al. Trovafloxin-induced acute hepatitis. Clin Infect Dis 2000 30 : 400 401.
24. Lucena MI, Andrade RJ, Fernadez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate heptotoxicity: a prospective study from Spain. Hepatology 2006 44 : 850 856.
25. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005 42 : 481 489.
26. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005 33 : 1 5.
27. Suzuki A, Andrade RJ, Bjornsson E, et al. Unified list of drugs associated with hepatotoxicity and the reporting frequency of liver events in the WHO Vigibase: International Collaborative work. Drug Saf 2010 [Epub ahead of print].
28. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993 46 : 1323 1330.
29. Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis 2009 29 : 348 356.
30. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008 135 : 1924 1934.
31. Kleiner DE. The pathology of drug-induced liver disease. Sem Liv Dis 2009 29 : 364 372.
32. Korman JD, Volenberg I, Balko J, et al. Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2008 48 : 1167 1174.
33. Raja K, Thung SN, Fiel MI, Chang C. Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis 2009 29 : 423 428.
34. Verrotti A, Di Marco G, la Torre R, Pelliccia P, Chiarelli F. Nonalcoholic fatty liver disease during valproate therapy. Eur J Pediatr 2009 168 : 1391 1394.
35. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007 56 : 1404 1409. (Pubitemid 47517834)
36. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003 125 : 298 303.
37. Black M, Mitchell JR, Zimmerman HJ, et al. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975 69 : 289 302.
38. Benjamin SB, Goodman ZD, Ishak KG, et al. The morphologic spectrum of halothane-induced hepatic injury: analysis of 77 cases. Hepatology 1985 5 : 1163 1171.
39. Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006 38 : 33 8.
40. Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006 44 S132 9.
41. Gayle F, Lee MG, Hanchard B, Mills M. Steatohepatitis due to antiretroviral therapy. West Indian Med J 2008 57 : 66 9.
42. Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A. Nodular regenerative hyperplasia of liver as a consequence of ART. let V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, Pol S. AIDS 2007 21 : 187 192.
43. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008 6 : 1167 1169.
44. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004 10 : 1018 1023.
45. Ibanez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002 37 : 592 600.
46. Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res 2009 39 : 427 431.
47. Chun LJ, Tong MJ, Busuttil RW, et al. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009 43 : 342 349.
48. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999 44 : 731 735.
49. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006 44 : 1581 1588.
50. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001 33 : 123 130.
51. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007 47 : 513 539.
52. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009 49 : 2001 2009.
53. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2009 51 : 615 620.
54. Suzuki A, Yuen N, Walsh J, Papay J, Hunt CM, Diehl AM. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol 2009 7 : 882 888.
55. Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988 8 : 599 606.
56. Oikawa H, Maesawa C, Sato R, et al. Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report. World J Gastroenterol 2005 11 : 5394 5397.
57. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991 90 : 711 716.
58. Russell RI, Allan JG, Patrick R. Active chronic hepatitis after chlorpromazine ingestion. Br Med J 1973 1 : 655 656.
59. Yeung E, Wong FS, Wanless IR, et al. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 2003 127 : 1493 1497.
60. Mazeika PK, Ford MJ. Chronic active hepatitis associated with diclofenac sodium therapy. Br J Clin Pract 1989 43 : 125 126.
61. Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977 72 : 610 616.
62. Olsson R, Wiholm BE, Sand C, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992 15 : 154 161.
63. Pineda JA, Larrauri J, Macias J, et al. Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine. J Hepatol 1999 31 : 777 778.
64. Poncin E, Silvain C, Touchard G, Barbier J, Beauchant M. Papaverine-induced chronic liver disease. Gastroenterology 1986 90 : 1051 1053.
65. Arranto AJ, Sotaniemi EA. Histologic follow-up of alpha-methyldopa- induced liver injury. Scand J Gastroenterol 1981 16 : 865 872.
66. Tonder M, Nordoy A, Elgjo. Sulfonamide-induced chronic liver disease. Scand J Gastroenterol 1974 9 : 93 6.
67. Kronborg IJ, Evans DT, Mackay IR, Bhathal PS. Chronic hepatitis after successive halothane anesthetics. Digestion 1983 27 : 123 128.
68. Seaman WE, Ishak KG, Plotz PH. Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus. Ann Intern Med 1974 80 : 1 8.
69. Babany G, Larrey D, Pessayre D, Degott C, Rueff B, Benhamou JP. Chronic active hepatitis caused by benzarone. J Hepatol 1987 5 : 332 335.
70. Johnston DE, Wheeler DE. Chronic hepatitis related to use of fluoxetine. Am J Gastroenterol 1997 92 : 1225 1226.
71. Volbeda F, Jonker AM, Vecht J, Groeneveld PH. Liver cirrhosis due to chronic use of nitrofurantoin. Ned Tijdschr Geneeskd 2004 31 : 148.
72. Brown PJE, Lesna M, Hamlyn AM, Record CO. Primary biliary cirrhosis after long-term practolol administration. Brit Med J 1978 1 : 1591.
73. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009 137 : 856 864.
74. Dertinger S, Dirschmid K, Vogel W, Drexel H. Immunosuppressive therapy for carbamazepine-induced hypersensitivity syndrome and hepatitis. J Hepatolog 1998 28 : 356 357.
75. Bacardi R. Report from the European association for the study of the liver (EASL). Randomised trial of steroid therapy in acute liver failure. Gut 1979 20 : 620 623.
76. Dechene A, Treichel U, Gerken G, et al. Effectiveness of a steroid and ursodexycholic acid combination therapy with drug-induced subacute liver failure. Hepatology 2005 42 : 358A.
77. Björnsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced Autoimmune Hepatitis: clinical characteristics and prognosis. Hepatology 2010 [Epub ahead of print].
78. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009 47 : 101 111.
79. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005 42 : 1364 1372.
80. Polson J, Wians FH Jr., Orsulak P, et al. False positive acetaminophen concentrations in patients with liver injury. Clin Chim Acta 2008 391 : 24 30.
81. Prior MJ, Cooper K, Cummins P, et al. Acetaminophen availability increases in Canada with no increase in the incidence of reports of inpatient hospitalizations with acetaminophen overdose and acute liver toxicity. Am J Ther 2004 11 : 443 452.
82. Myers RP, Shaheen AAM, Li B, Dean S, Quan H. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol 2008 6 : 918 925.
83. Zimmerman H. Acetaminophen hepatotoxicity. Clin Liv Dis 1998 2 : 523 541.
84. Seef LB, Cuccherini BA, Zimmerman H, et al. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 1986 104 : 399 404.
85. McClain CJ, Holtzman J, Allen J, et al. Clinical features of acetaminophen toxicity. J Clin Gastroenterol 1988 10 : 55 9.
86. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. A randomized controlled trial. JAMA 2006 296 : 87 93.
87. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994 272 : 1845 1850.
88. Rumack BH. Acetaminophen misconceptions. Hepatology 2004 40 : 10 5.
89. Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002 35 : 876 882.
90. Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminopen overdose in the united states: a nationwide study. Hepatology 2008 48 : 1336 1341.
91. Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients. A randomized double-blind, placebo-controlled trial. Arch Intern Med 2001 161 : 2247 2252.
92. Benson G, Koff R, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Therap 2005 12 : 133 141.
93. Bartels S, Sivilotti M, Crosby D, Richard J. Are recommended doses of acetaminophen hepatotoxic for recently abstinent alcoholics? A randomized trial. Clin Toxicol (Phila) 2008 46 : 243 249.
94. Shayiq RM, Roberts DW, Rothstein K, et al. Repeat exposure to incremental doses of acetaminophen (paracetamol) provides protection against acetaminophen-lethality in mice: an explanantion for high acetaminophen dosage in humans. Hepatology 1999 31 : 777 778.